Factors Associated with Severe Human Rift Valley Fever in Sangailu, Garissa County, Kenya

PLoS Neglected Tropical Diseases

Volumn 9, Issue 3, 2015, Pages

  LaBeaud, A Desirée ^a,b   Pfeil, Sarah ^b   Muiruri, Samuel ^c   Dahir, Saidi ^c   Sutherland, Laura J ^d   Traylor, Zachary ^d   Gildengorin, Ginny ^b   Muchiri, Eric M ^c   Morrill, John ^e   Peters, C J ^e   Hise, Amy G ^d,f   Kazura, James W ^d   King, Charles H ^d  

^a STANFORD UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c MINISTRY OF HEALTH   (Kenya)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ANIMAL HUSBANDRY; ARTICLE; CHILD; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE EXAMINATION; FEMALE; GENDER; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SEROPREVALENCE; VERY ELDERLY; VIRUS NEUTRALIZATION; VISUAL ACUITY; ANIMAL; BLOOD; EPIDEMIC; IMMUNOLOGY; MIDDLE AGED; PREVALENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMAL HUSBANDRY; ANIMALS; ANTIBODIES, VIRAL; CHILD; CROSS-SECTIONAL STUDIES; DISEASE OUTBREAKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KENYA; MALE; MIDDLE AGED; PREVALENCE; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84928820494     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003548     Document Type: Article

References (23)

1. Anyangu AS, Gould LH, Sharif SK, Nguku PM, Omolo JO, et al. (2010) Risk factors for severe Rift Valley fever infection in Kenya, 2007. Am J Trop Med Hyg 83: 14–21. doi: 10.4269/ajtmh.2010.09-0293 20682901
2. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, et al. (2002) An outbreak of Rift Valley fever in Northeastern Kenya, 1997–98. Emerg Infect Dis 8: 138–144. 11897064
3. Breiman RF, Minjauw B, Sharif SK, Ithondeka P, Njenga MK, (2010) Rift Valley Fever: scientific pathways toward public health prevention and response. Am J Trop Med Hyg 83: 1–4. doi: 10.4269/ajtmh.2010.83s2a01 20824895
4. CDC (2007) Rift Valley Fever. Viral Hemorrhagic Fevers: Fact Sheets. pp.1–3.
5. LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, et al. (2008) Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. Emerg Infect Dis 14: 1240–1246. doi: 10.3201/eid1408.080082 18680647
6. LaBeaud AD, Muiruri S, Sutherland LJ, Dahir S, Gildengorin G, et al. (2011) Postepidemic analysis of Rift Valley fever virus transmission in northeastern Kenya: a village cohort study. PLoS Negl Trop Dis 5: e1265. doi: 10.1371/journal.pntd.0001265 21858236
7. European Food Safety Authority (2005) Opinion of the scientific panel on animal health and welfare on a request from the Commission related to "The risk of a rift valley fever incursion and its persistence within the community". EFSA Journal. pp. 1–128.
8. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowder GD, (2011) Potential effects of Rift Valley fever in the United States. Emerg Infect Dis 17: e1. doi: 10.3201/eid1709.110506 21888781
9. Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, et al. (2010) Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg 82: 371–375. doi: 10.4269/ajtmh.2010.09-0669 20207858
10. Al-Hazmi A, Al-Rajhi AA, Abboud EB, Ayoola EA, Al-Hazmi M, et al. (2005) Ocular complications of Rift Valley fever outbreak in Saudi Arabia. Ophthalmology 112: 313–318. 15691569
11. Niklasson B, Grandien M, Peters CJ, Gargan TP, 2nd (1983) Detection of Rift Valley fever virus antigen by enzyme-linked immunosorbent assay. J Clin Microbiol 17: 1026–1031. 6409920
12. LaBeaud AD, Ochiai Y, Peters CJ, Muchiri EM, King CH, (2007) Spectrum of Rift Valley fever virus transmission in Kenya: insights from three distinct regions. Am J Trop Med Hyg 76: 795–800. 17488893
13. Meadors GF, 3rdGibbs PH, Peters CJ, (1986) Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine 4: 179–184. 3532605
14. Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, et al. (1991) Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9: 35–41. 2008798
15. Norusis MJ, (2008) Cluster Analysis. SPSS Statistics 17- Statistical Procedures Companion. Upper Saddle River, NJ: Prentice Hall. pp. 359–388.
16. Chen D, Getis A, (1998) Point Pattern Analysis. San Diego State University. San Diego, CA.
17. Getis A, (1984) Interaction modeling using second-order analysis. Environment and Planning A 16 173–183.
18. Getis A, Ord J, Longley P, Batty M, (1996) Local spatial statistics: an overview; Spatial Analysis: Modelling in a GIS Environment. Cambridge: Geoinformation International. 261–277 p.
19. Nguku PM, Sharif SK, Mutonga D, Amwayi S, Omolo J, Mohammed O, Farnon EC, Gould LH, Lederman E, Rao C, Sang R, Schnabel D, Feikin DR, Hightower A, Njenga MK, Breiman RF, An investigation of a major outbreak of Rift Valley fever in Kenya: 2006–2007. Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):5–13. doi: 10.4269/ajtmh.2010.09-0288 20682900
20. Riou O, Philippe B, Jouan A, Coulibaly I, Mondo M, et al. (1989) [Neurologic and neurosensory forms of Rift Valley fever in Mauritania]. Bull Soc Pathol Exot Filiales 82: 605–610. 2633869
21. Anninger W, Lubow M, (2004) Visual loss with West Nile virus infection: a wider spectrum of a "new" disease. Clin Infect Dis 38: e55–56. 15034847
22. Khairallah M, Chee SP, Rathinam SR, Attia S, Nadella V, (2010) Novel infectious agents causing uveitis. Int Ophthalmol 30: 465–483. doi: 10.1007/s10792-009-9319-6 19711015
23. Koevary SB, (2005) Ocular involvement in patients infected by the West Nile virus. Optometry 76: 609–612. 16230277